Lenalidomide (CC-5013)

製品コードS1029

Lenalidomide (CC-5013)化学構造

分子量(MW):259.26

Lenalidomide (CC-5013)は一種のTNF-α分泌阻害剤で、PBMCsの中にIC50値が13 nMです。

サイズ 価格 在庫  
JPY 27516.10 あり
JPY 21166.23 あり
JPY 82073.16 あり

カスタマーフィードバック(4)

  • MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure.

    Clin Cancer Res, 2011, 17(10): 3259–71. Lenalidomide (CC-5013) purchased from Selleck.

     

    Effect of lenalidomide treatment (50 mg/kg/day, p.o. for 3 days) on expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), Fas, Fas ligand (FasL), and cleaved caspase-3 in myocardium from lean and ob/ob mice. (a) Representative gel blots of TNF-α, IL-6, Fas, FasL, cleaved caspase-3 and α-Tubulin (as loading control) using specific antibodies. (b) TNF-α.

    Obesity 2012 20, 2174-85. Lenalidomide (CC-5013) purchased from Selleck.

  • MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure. B) MM.1S cells were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 4 hours. Whole lysates were immunoblotted with indicated antibodies

     

     

    Harvard Medical School. Lenalidomide (CC-5013) purchased from Selleck.

    MM.1S cells were cultured for 48 hours in the presence or absence of BMSCs with control media, AT9283, lenalidomide or  AT9283 plus lenalidomide. Cell proliferation was assessed by 3H-TdR uptake (left). MM.1S cells were cultured in the absence or presence of BMSCs and treated for 4 hours with drugs alone or in combination. Whole lysates were immunoblotted with indicated antibodies.

     

     

    Harvard Medical School. Lenalidomide (CC-5013) purchased from Selleck.

製品安全説明書

TNF-alpha阻害剤の選択性比較

生物活性

製品説明 Lenalidomide (CC-5013)は一種のTNF-α分泌阻害剤で、PBMCsの中にIC50値が13 nMです。
ターゲット
TNF-α [1]
(PBMCs)
13 nM
体外試験

Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LB771-HNC MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJwMUWwN|gh|ryP MUHTRW5ITVJ?
L-363 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXnUIpKSzVyPUKuPVIzOTJizszN MorGV2FPT0WU
JAR NFLSNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjzTWM2OD1{Lkm3NFAyKM7:TR?= M{nVSnNCVkeHUh?=
EoL-1-cell M2nYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwMUC1NVUh|ryP NWHrdmdjW0GQR1XS
BT-549 M4PtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYToToY2UUN3ME22MlIyQDR7IN88US=> MYXTRW5ITVJ?
SK-NEP-1 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTdwOEm1NVIh|ryP MoLjV2FPT0WU
BV-173 NVfMXVBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nu[mlEPTB;OD62O|U5PSEQvF2= NXPCTXdSW0GQR1XS
HMV-II NIC4TnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;PTWM2OD1zMD6wNVczKM7:TR?= NYGy[oVmW0GQR1XS
HCC1806 M2LWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnhVIxOUUN3ME2xNU41PDZ5IN88US=> MYjTRW5ITVJ?
KASUMI-1 MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHwNlJKSzVyPUGxMlU4OSEQvF2= NXjpTZRmW0GQR1XS
SK-MEL-28 NHm4cFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\QR2lEPTB;MUGuPVc3PCEQvF2= M2Dzb3NCVkeHUh?=
RPMI-8226 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTHVmFKSzVyPUGyMlYzPDFizszN M3vuSXNCVkeHUh?=
T47D NFn6cINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3PRVBDUUN3ME2xN{4zODl7IN88US=> NWPMTlNQW0GQR1XS
HOP-62 NGjEOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy3NYRKSzVyPUGzMlQ5KM7:TR?= MoT4V2FPT0WU
A2058 Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rObmlEPTB;MUOuPFE6QSEQvF2= NUfKU5pUW0GQR1XS
SW620 NEH2XXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm5UXBCUUN3ME2xOE4zPDd|IN88US=> MV7TRW5ITVJ?
LCLC-103H MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF2LkS4PVIh|ryP M{K1TXNCVkeHUh?=
HAL-01 M3PBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33tdWlEPTB;MUSuOVc6PiEQvF2= M2j5cHNCVkeHUh?=
PANC-08-13 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnBPY9KSzVyPUG0MlkyODhizszN MXzTRW5ITVJ?
COLO-684 NGjuNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:yN3VKSzVyPUG1MlM6PzlizszN MVTTRW5ITVJ?
DEL NHfUcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXCTWM2OD1zNT60PVkh|ryP NULwU5NkW0GQR1XS
K5 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjDSGIzUUN3ME2xOk4yPDh4IN88US=> MX7TRW5ITVJ?
SK-MEL-24 NUHVPXZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLqcVdKSzVyPUG2MlQ3PTJizszN MoXHV2FPT0WU
ACN NYDvN45CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv3VI9vUUN3ME2xOk42Ojl5IN88US=> MmjJV2FPT0WU
H9 MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DkT2lEPTB;MU[uOlI3KM7:TR?= M1TLSnNCVkeHUh?=
EM-2 NVzPRWt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnjTWM2OD1zNz6xOFMh|ryP NFjXSGxUSU6JRWK=
HSC-4 NEXmbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDCTHJKSzVyPUG3MlY3ODFizszN M3;zWXNCVkeHUh?=
IGROV-1 M3G2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTTTWM2OD1zNz63PFMh|ryP M1HNbnNCVkeHUh?=
TE-1 M136N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDlTWM2OD1zNz65PVY5KM7:TR?= NYnrN4syW0GQR1XS
LN-405 M3X3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvxPVFyUUN3ME2xPU46ODd4IN88US=> M164RXNCVkeHUh?=
MSTO-211H NYPwRVR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TwfmlEPTB;MkCuN|U4OyEQvF2= NIHVXmFUSU6JRWK=
MOLT-4 MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TwVWlEPTB;MkCuOVc2QSEQvF2= NVLPeppSW0GQR1XS
RS4-11 NXzCc282T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L1XmlEPTB;MkKuNVU3OyEQvF2= MoqwV2FPT0WU
ES3 NIDnbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Lm[2lEPTB;MkKuOlk3OyEQvF2= NV\JenBKW0GQR1XS
SBC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ|Lki2PVYh|ryP NX34bmJqW0GQR1XS
CTV-1 NX;rZVdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TE[GlEPTB;MkWuNFE1QSEQvF2= MUTTRW5ITVJ?
HuP-T3 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljDTWM2OD1{NT60NFA6KM7:TR?= NYDYdJJRW0GQR1XS
HCC2218 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJ3LkW0NFch|ryP MkK4V2FPT0WU
HDLM-2 Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ6LkKwNlYh|ryP MUjTRW5ITVJ?
ABC-1 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\5TWM2OD1{OT62PVc1KM7:TR?= NVrLU2FRW0GQR1XS
MV-4-11 M4Lhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3nTWM2OD1{OT63N|E4KM7:TR?= NGLVfItUSU6JRWK=
WM-115 M3TsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGizfIRKSzVyPUOwMlMxQTlizszN M1HUWXNCVkeHUh?=
SW1990 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGyOolKSzVyPUOwMlM{KM7:TR?= MYfTRW5ITVJ?
HCC70 NFvXNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPuTWM2OD1|MD63N|Q3KM7:TR?= M1W1e3NCVkeHUh?=
KYSE-520 NVfHU3lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jGUmlEPTB;M{CuPFg{QSEQvF2= MoHLV2FPT0WU
JEG-3 M2S3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETZUVZKSzVyPUOxMlE3OTRizszN MYnTRW5ITVJ?
C8166 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\MWWlEPTB;M{GuNlI4PCEQvF2= MnPKV2FPT0WU
SK-OV-3 NWn5NWRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNzLk[3OVUh|ryP MVXTRW5ITVJ?
NCI-H526 NH7S[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTkZ5k{UUN3ME2zNk43QDNizszN MluwV2FPT0WU
NKM-1 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ricWlEPTB;M{KuPVU3QCEQvF2= MlG0V2FPT0WU
ECC10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH1NpJKSzVyPUO0Mlc1PDNizszN NVzITYl1W0GQR1XS
A2780 MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TKbWlEPTB;M{WuN|YxOSEQvF2= MnPaV2FPT0WU
KY821 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnLN|NKSzVyPUO1Mlc3QDFizszN NFi3SpJUSU6JRWK=
MKN1 NWS2SpZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTN4LkKxN|ch|ryP NFLieJZUSU6JRWK=
EKVX M3rLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfq[pRKSzVyPUO3MlQzOTJizszN NF\VUINUSU6JRWK=
EW-16 NULTOlVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHCWHRKSzVyPUO4MlM5QDVizszN M4rFXnNCVkeHUh?=
CTB-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PSRWlEPTB;M{muO|c5QSEQvF2= M1;UNnNCVkeHUh?=
COR-L105 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD3NWFWUUN3ME20NE41PzR4IN88US=> NGfqNoZUSU6JRWK=
NCI-SNU-5 NHnCZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH5TWM2OD12MT6yNFY6KM7:TR?= NUDHUoFyW0GQR1XS
Mewo MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7sTWM2OD12MT65PFcyKM7:TR?= NYfNW|YzW0GQR1XS
BCPAP MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTR|Lke5NVch|ryP MoPTV2FPT0WU
KARPAS-45 MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTR2LkK3O|Yh|ryP NGTudYhUSU6JRWK=
NCI-H1693 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLLeHJZUUN3ME20Ok43QTh4IN88US=> NF3pT5BUSU6JRWK=
H-EMC-SS NWniZmI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PsNGlEPTB;NEiuN|IzPCEQvF2= MVrTRW5ITVJ?
697 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7oTWM2OD13MD6zOVQ2KM7:TR?= NXvscFJVW0GQR1XS
KP-N-YS MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LnSGlEPTB;NUKuN|E1OiEQvF2= NVHaNlZbW0GQR1XS
NCI-H1304 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKyXnJKSzVyPUWyMlcxOjRizszN NWDudoF[W0GQR1XS
NOS-1 M4D6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf6TWM2OD13Mj64OVU6KM7:TR?= NH\BNZVUSU6JRWK=
NCI-H2342 M2qweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\jO2lEPTB;NUOuNFUxQCEQvF2= NXfhSWtvW0GQR1XS
KYSE-270 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnIeosyUUN3ME21N{43OzZ2IN88US=> MmPIV2FPT0WU
LU-135 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTV3LkG4OVMh|ryP M{XXVnNCVkeHUh?=
OE33 M1m5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;xdZdXUUN3ME21OU45OThizszN MXXTRW5ITVJ?
ML-2 M1jxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXpRpZGUUN3ME21OU46PDh7IN88US=> MnTNV2FPT0WU
KMOE-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnyyTWM2OD13Nj6yPFk{KM7:TR?= MXLTRW5ITVJ?
Daoy MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe4TWM2OD13Nj6zNlA1KM7:TR?= MUXTRW5ITVJ?
KNS-62 NIrFfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTV5LkCxOFIh|ryP NIn5NmhUSU6JRWK=
NBsusSR NGn5do1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTV5LkW3NFUh|ryP MkPyV2FPT0WU
UACC-257 NY[4OJp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTV6Lk[yOlQh|ryP NXjBeHc3W0GQR1XS
LU-139 NHfrN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLhV3BpUUN3ME21PE45OjZizszN MnP2V2FPT0WU
CAL-85-1 M1\6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PEVGlEPTB;NUiuPFY1OyEQvF2= MWLTRW5ITVJ?
NCI-H720 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HiSWlEPTB;NUiuPFk1OiEQvF2= NWDlUZdtW0GQR1XS
MLMA MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTV7LkC5NUDPxE1? MnvlV2FPT0WU
A3-KAW MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\CXGlEPTB;NUmuNlgxQSEQvF2= M{m3Z3NCVkeHUh?=
Ramos-2G6-4C10 NEDPdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzFTWM2OD13OT62Nlg4KM7:TR?= Mnv4V2FPT0WU
A388 NF75OINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rkSmlEPTB;NkCuOFQ6KM7:TR?= M1PyOnNCVkeHUh?=
LAMA-84 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3ubXdKSzVyPU[wMlk6ODVizszN Mm\5V2FPT0WU
GCT NXfpd4FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\nXotKSzVyPU[xMlA4QDZizszN NVK0TJR5W0GQR1XS
K-562 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rjZWlEPTB;NkGuOVM{OyEQvF2= M{jxWXNCVkeHUh?=
NCI-H1666 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTZzLki3OUDPxE1? NGPNOIZUSU6JRWK=
NCI-H1993 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTZ|LkSwOFMh|ryP MXvTRW5ITVJ?
NCI-H358 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17lPWlEPTB;NkWuNFEzOSEQvF2= NWTISW9HW0GQR1XS
NB6 MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HHZmlEPTB;NkWuPVg5KM7:TR?= MoDJV2FPT0WU
HCE-T M2rqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHmS3FKSzVyPU[3MlA4QThizszN NHjlVXJUSU6JRWK=
DOK M2WwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEmwcIJKSzVyPU[3MlQ6PDhizszN NXnXVHE5W0GQR1XS
HT-1376 M3HjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr4d2FKSzVyPU[5Mlg{OTRizszN NFSzNYFUSU6JRWK=
NEC8 M4nFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\PfmhKSzVyPUewMlEzPDNizszN Mn;wV2FPT0WU
G-402 NX\tbJFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTdyLkmzPVUh|ryP M4nDUnNCVkeHUh?=
GR-ST NIDTTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zUR2lEPTB;N{GuNVczKM7:TR?= MUTTRW5ITVJ?
QIMR-WIL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXwTWM2OD15MT60OFM1KM7:TR?= MnjKV2FPT0WU
CHP-212 M17aT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X3ZmlEPTB;N{GuPVY2KM7:TR?= MWfTRW5ITVJ?
KU812 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrsTWM2OD15Mj65O|AzKM7:TR?= MXPTRW5ITVJ?
Becker NIHjXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfXdZpKSzVyPUezMlE1QDlizszN NF7aZWdUSU6JRWK=
ChaGo-K-1 NYe0XFVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLkTWM2OD15ND63OFg3KM7:TR?= NHrwc5FUSU6JRWK=
A498 NFn4fmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LjU2lEPTB;N{SuPVMxQCEQvF2= M2j6e3NCVkeHUh?=
NCI-H69 M1LTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vYWGlEPTB;N{WuO|Y3OyEQvF2= NX\SWmRwW0GQR1XS
NCI-H209 NYTXd4dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfIRnlKSzVyPUe4MlYyPDdizszN MkXvV2FPT0WU
CAL-33 NWC3T3BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoSwTWM2OD15OD65PVM6KM7:TR?= MWnTRW5ITVJ?
COLO-680N MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\vbmlEPTB;N{muNVAxPyEQvF2= M2GzPHNCVkeHUh?=
D-283MED M{HpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7UfoFKSzVyPUe5MlgyOiEQvF2= M3fY[XNCVkeHUh?=
ATN-1 NIO5R|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX5TYtKSzVyPUixMlEyQDdizszN NGTDPG9USU6JRWK=
NCI-N87 NILwN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\XU2lEPTB;OEGuO|I6PiEQvF2= M{j6[nNCVkeHUh?=
MHH-NB-11 NUS3TGd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;QPWRKSzVyPUixMlg5PDlizszN NV\uZ5E2W0GQR1XS
HEL NYL0V2Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHrcI9PUUN3ME24Nk41OTN2IN88US=> NVnNU|d[W0GQR1XS
NB69 NEjuZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK1TWM2OD16Mz6wNFM{KM7:TR?= MXzTRW5ITVJ?
MPP-89 NXTtWm9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jmNWlEPTB;OEOuNlU4PSEQvF2= MoHGV2FPT0WU
COLO-829 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfZTWM2OD16NT60PVEzKM7:TR?= NVjCfG12W0GQR1XS
ONS-76 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\COXVKSzVyPUi1Mlc6ODhizszN NHrXWoFUSU6JRWK=
EW-3 Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXDTWZKSzVyPUi2MlIxOzJizszN Ml3nV2FPT0WU
EW-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH0NmdzUUN3ME24Ok41OzN4IN88US=> NHzoUYNUSU6JRWK=
SW900 NIn5[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTh5LkKwOVMh|ryP NVGxcHExW0GQR1XS
MOLT-13 M1yyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXDVIlKSzVyPUi3MlIzPDNizszN MmnKV2FPT0WU
HuP-T4 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPsTWM2OD17MT6wOFA2KM7:TR?= M{n5SnNCVkeHUh?=
HCC1419 M3i1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjHXHhKSzVyPUmxMlY{PzRizszN M3Pvd3NCVkeHUh?=
CAL-72 M{D1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zseGlEPTB;OUKuNFIyQSEQvF2= MljqV2FPT0WU
Mo-T M{PEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LDOmlEPTB;OUKuO|Y6PyEQvF2= M3W1[nNCVkeHUh?=
OC-314 M4S3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj2SYNKSzVyPUmyMlg5OjFizszN NHnjS49USU6JRWK=
BHT-101 NVOxeFhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXwTWM2OD17Mz6xJO69VQ>? NVTmZWVFW0GQR1XS
EW-18 M3HTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLFTWM2OD17Mz64OFYzKM7:TR?= M3Tx[XNCVkeHUh?=
TE-12 NYD0PWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTlTWM2OD17ND6zNFU2KM7:TR?= MULTRW5ITVJ?
MDA-MB-361 M3vXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HDRWlEPTB;OU[uNFUyPiEQvF2= M4H2PHNCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5]

お薦めの試験操作(参考用のみ)

動物試験:

[5]

+ 展開
  • 動物モデル: Adult male Sprague-Dawley rats bearing HUVECs cells
  • 製剤: 0.5% DMSO
  • 投薬量: 50 mg/kg and 250 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (200.57 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% PEG 400+0.5% Tween 80+5% propylene glycol+H2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 259.26
化学式

C13H13N3O3

CAS No. 191732-72-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02871219 Recruiting Follicular Lymphoma M.D. Anderson Cancer Center|Genentech, Inc. December 6, 2016 Phase 2
NCT00540007 Completed Hodgkin Disease Washington University School of Medicine|Celgene Corporation September 6, 2007 Phase 2
NCT01629082 Completed Myeldysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia|Bone Marrow Diseases|Neutropenia|Acute Myeloid Leukemia (AML) National Heart, Lung, and Blood Institute (NHLBI)|Celgene Corporation|National Institutes of Health Clinical Center (CC) June 5, 2012 Phase 1
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT02225275 Recruiting Leukemia M.D. Anderson Cancer Center|Genentech, Inc.|Celgene Corporation March 31, 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is the formulation for mouse injection(i.p.)?

  • 回答:

    This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.

  • 問題2:

    what is the procedure to resuspend this compound?

  • 回答:

    You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.

TNF-alpha信号経路図

TNF-alpha Inhibitors with Unique Features

相関TNF-alpha製品

Tags: Lenalidomide (CC-5013)を買う | Lenalidomide (CC-5013) ic50 | Lenalidomide (CC-5013)供給者 | Lenalidomide (CC-5013)を購入する | Lenalidomide (CC-5013)費用 | Lenalidomide (CC-5013)生産者 | オーダーLenalidomide (CC-5013) | Lenalidomide (CC-5013)化学構造 | Lenalidomide (CC-5013)分子量 | Lenalidomide (CC-5013)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID